Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in pretreated poor performance status patients with T790M-positive advanced non-small-cell lung cancer
jRCTs061180018Completed
- Sponsor
- Not applicable
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Not applicable. Primary endpoint: Objective response rate. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061180018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180018.